 |
| Organic structures are printed here |
The research project aims to solve one of tissue engineering’s toughest problems: creating printable bio-inks that can rebuild the fibrous architecture of real human tissue.
3D bioprinting has long been viewed as a potential answer to the global shortage of donor organs. The idea is compelling: instead of waiting for a suitable donor, doctors could one day print implantable, patient-specific organs or tissue patches on demand. The same technology could also produce diseased tissue models for drug discovery, allowing researchers to test new therapies on human-like tissue without relying solely on animal studies.
But the field has a bottleneck. The bio-inks used in 3D bioprinting must be liquid enough to flow through a printer nozzle, stable enough to hold a shape, and gentle enough to keep living cells alive. At the same time, they must be able to recreate the natural, fibrous structure of human tissue. So far, most materials have struggled to do all of these things at once.
That is where the Fraunhofer-led PhysioINK project comes in. Researchers at several Fraunhofer institutes are developing new bio-inks made from collagen and elastin—the structural proteins that make up a large portion of human tissue. Instead of relying on synthetic or heavily chemically modified materials, the team is using physiological proteins, the same type of material found in real organs.
The printability problem in 3D bioprinting
The challenge is not simply making an ink that can be printed. It is making an ink that can be printed and then reorganize itself into something that behaves like living tissue.
Collagen and elastin are essential to the mechanical and biological properties of soft tissue. Depending on the tissue type, they can account for 60 to 100 percent of its structure. For printed tissue to function properly, these proteins need to return to their natural fibrous or network-like arrangement. In scientific terms, this is known as protein reorganization.
If collagen is left to its own devices, it will naturally self-assemble into tiny thread-like fibers called fibrils. That sounds useful—and it is, in the body. But in a printing cartridge, it is a problem. Once collagen forms fibrils, it becomes difficult to shape and print. The material gels or clumps, losing the flow properties needed for precise 3D printing.
Conventional bio-inks often solve this by using synthetic polymers or chemically modified collagen. These materials may print well, but they do not fully mimic human tissue. Other inks may mimic tissue structure better, but they are not printable enough for practical use. The PhysioINK team is trying to break that trade-off.
How cellulose sulfate and temperature trigger a solution
The Fraunhofer researchers have developed a mechanism that temporarily stabilizes collagen and elastin so they can be printed, then triggers them to self-organize after printing.
The key is cellulose sulfate, a sustainable cellulose derivative. According to Fraunhofer, the team packages positively charged collagen and elastin molecules with negatively charged macromolecules based on cellulose sulfate. The cellulose sulfate binds to the collagen and prevents it from reorganizing too early. This keeps the proteins in a dissolved, printable state.
As Fraunhofer explains in a recent press release on sustainable printing inks for functional organs, the cellulose sulfate acts as a temporary brake. It stabilizes the ink so it can be used in a printer. Then, after printing, a temperature trigger—specifically an increase in temperature—removes that stabilization. The collagen and elastin are free to self-organize again, reforming their natural fibrous or network-like structure.
This approach has already been submitted for a patent. Based on the principle, the project partners are developing three different bio-inks: one based on collagen type I, one based on collagen type IV, and one based on elastin. Longer term, the researchers hope to adapt the method to other proteins by adjusting the cellulose sulfate accordingly.
From fridge stability to printed skin models
A printable bio-ink also has to survive real-world handling. It must remain stable during storage, shipping, and use. The PhysioINK team has been testing exactly that.
The collagen type I ink has shown stability in the refrigerator at 4 degrees Celsius without gelling. So far, the longest storage period tested is around nine months. The ink can also be frozen at minus 20 degrees Celsius without losing its gelling properties.
Shipping tests between project partners have also produced encouraging results. In one case, cooled samples packed with cooling pads arrived within 24 hours at 2.8 degrees Celsius under moderate weather conditions. In another test, a shipment took 48 hours in extreme weather and arrived at 8.0 degrees Celsius. Both cases suggest that shipments within Germany can be handled reliably within a 48-hour delivery window.
For printing, the researchers tested collagen type I ink at three, five, and seven percent concentrations using different print nozzles. At three percent, the ink still flowed too much after printing or during gelation. At five and seven percent, however, free-standing prints were possible. The team has already successfully printed initial skin tissue models, demonstrating that the collagen type I ink can be used in practice.
One particularly promising feature is real-time monitoring of human cell metabolism. This allows researchers to continuously check the nutrient supply of the printed cell tissue. In turn, they can assess the quality of printed tissue structures and optimize their architecture more precisely.
Why this matters for organ printing and drug development
The implications go beyond lab curiosity. In Germany alone, around 8,000 people are on an organ donation waiting list each year, and roughly ten percent wait in vain. 3D bioprinting is considered a possible long-term solution to the worldwide shortage of donor organs. It could make it possible to produce implantable, patient-specific organs or organ parts automatically.
The technology could also support the printing of pathological tissue models—diseased tissue used to study illness and test new drugs. The PhysioINK project has two planned applications: standardized intestinal tumor models for drug development and physiological heart tissue as a step toward functional implants for personalized, regenerative medicine.
The project involves several Fraunhofer institutes. Fraunhofer ISC coordinates the work and focuses on collagen gels and inks, 3D cell culture, and bioreactors. Fraunhofer IAP handles cellulose chemistry and characterization. Fraunhofer IMWS contributes protein characterization and bioprinting. Fraunhofer IZI-BB analyzes macromolecular interactions and works on cell culture and monitoring systems. The Technical University of Würzburg-Schweinfurt is supporting the consortium with AI-based data collection, preparation, and evaluation. Companies including AbbVie Deutschland, GfN-Selco/KBM, and Black Drop Biodrucker are advising the team.
The project runs from February 2025 to January 2028 and is funded through internal Fraunhofer programs.
A more physiological approach to bio-ink
Cost pressures have led most current printing inks to use animal-derived and strongly modified collagens. These materials can be printed, but they only partially reflect human physiology. PhysioINK is taking a different route: using physiological, ideally human, components.
That does not mean the challenges are over. The team still needs to prove that the inks work across different 3D printing methods, scale up production, and meet regulatory requirements for medical use. But the core idea—using cellulose sulfate as a temporary stabilizer and temperature as a trigger for natural protein self-organization—offers a new way to think about bio-ink design.
If successful, the technology could help move 3D bioprinting from promising laboratory concept to practical tool for regenerative medicine and drug discovery. For patients waiting for organs, that cannot come soon enough.
Key takeaways
- Fraunhofer’s PhysioINK project is developing bio-inks from collagen and elastin, the structural proteins found in human tissue.
- Cellulose sulfate temporarily stabilizes the proteins so they can be printed; a temperature increase then triggers natural self-organization.
- The approach has already produced early 3D-printed skin tissue models.
- Planned applications include intestinal tumor models for drug testing and physiological heart tissue for regenerative medicine.
- The project runs from February 2025 to January 2028 with multiple Fraunhofer institutes and industry partners.
